Format

Send to

Choose Destination
Scand J Gastroenterol. 2018 Feb;53(2):152-157. doi: 10.1080/00365521.2017.1410219. Epub 2017 Nov 30.

Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.

Author information

1
a Department of Gastroenterology , Hospital Santa Creu i Sant Pau , Barcelona , Spain.
2
b Universitat Autònoma de Barcelona , Bellaterra , Spain.
3
c Department of Gastroenterology , Hospital Universitari Germans Trias i Pujol , Badalona , Spain.
4
d Hepatic and Digestive Diseases , Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) , Madrid , Spain.
5
e Department of Gastroenterology, Instituto de Investigación Sanitaria Princesa (IIS-IP) , Hospital Universitario de La Princesa , Madrid , Spain.
6
f Department of Gastroenterology , Hospital Politècnic La Fe , Valencia , Spain.
7
g Department of Gastroenterology , Hospital Universitario de Santiago , Santiago de Compostela , Spain.
8
h Department of Gastroenterology , Hospital Clínic, IDIBAPS , Barcelona , Spain.
9
i Department of Gastroenterology , Hospital de Fuenlabrada , Fuenlabrada , Spain.
10
j Digestive System Service , Hospital Reina Sofía , Córdoba , Spain.
11
k Department of Gastroenterology , Consorci Sanitari Terrassa , Terrassa , Spain.
12
l Xarxa Hospitalària Althaia , Manresa , Spain.

Abstract

BACKGROUND:

Fecal calprotectin (FC) correlates with clinical and endoscopic activity in ulcerative colitis (UC), and it is a good predictor of relapse. However, its use in clinical practice is constrained by the need for the patient to deliver stool samples, and for their handling and processing in the laboratory. The availability of hand held devices might spread the use of FC in clinical practice.

OBJECTIVES:

To evaluate the usefulness of a rapid semi-quantitative test of FC in predicting relapse in patients with UC in remission.

MATERIALS AND METHODS:

Prospective, multicenter study that included UC patients in clinical remission for ≥6 months on maintenance treatment with mesalamine. Patients were evaluated clinically and semi-quantitative FC was measured using a monoclonal immunochromatography rapid test at baseline and every three months until relapse or 12 months of follow-up.

RESULTS:

One hundred and ninety-one patients had at least one determination of FC. At the end of follow-up, 33 patients (17%) experienced clinical relapse. Endoscopic activity at baseline (p = .043) and having had at least one FC > 60 μg/g during the study period (p = .03) were associated with a higher risk of relapse during follow-up. We obtained a total of 636 semi-quantitative FC determinations matched with a three-month follow-up clinical assessment. Having undetectable FC was inversely associated with early relapse (within three months), with a negative predictive value of 98.6% and a sensitivity of 93.9%.

CONCLUSIONS:

Serial, rapid semi-quantitative measurement of FC may be a useful, easy and cheap monitoring tool for patients with UC in remission.

KEYWORDS:

Fecal calprotectin; relapse; remission; semi-quantitative; ulcerative colitis

PMID:
29189092
DOI:
10.1080/00365521.2017.1410219
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center